Atrial natriuretic factor in hydrops fetalis caused by Rh isoimmunisation

F R Moya, P A T Grannum, L Riddick, J A Robert, J Pinheiro

Abstract
Plasma concentrations of atrial natriuretic factor were determined by radioimmunoassay in 16 human fetuses of between 19 and 38 weeks' gestation. Fifteen fetuses had varying degrees of anaemia as a result of Rh isoimmunisation, and one fetus was normal. Eight fetuses had ultrasonographic evidence of severe hydrops fetalis and an additional three fetuses had mild hydrops. Severely hydropic fetuses were more anaemic and immature than those with mild or no hydrops. Among fetuses from which samples were taken before in utero transfusion, concentrations of atrial natriuretic factor were higher in those with severe hydrops than in the other groups. An inverse relationship between the haemoglobin concentration and that of atrial natriuretic factor was found. In four fetuses in which severe hydrops resolved after intra-vascular transfusions in utero, there were significant decreases in plasma atrial natriuretic factor concentrations; in the fifth fetus the decrease was less pronounced.

Raised concentrations of atrial natriuretic factor in fetuses with severe anaemia and hydrops may be the result of atrial natriuretic factor release induced by hypoxia.

Several investigators have shown that human and animal fetuses synthesise and secrete atrial natriuretic factor into the circulation in response to various stimuli.1-3 Receptors for atrial natriuretic factor have been found in normal human and sheep placentas, which suggests that this peptide has a role in fetal fluid and electrolyte homoeostasis.4 5 In sheep, concentrations of atrial natriuretic factor are higher in lamb fetuses than in the ewes,6 7 and non-immune fetal hydrops caused by atrial pacing increased circulating concentrations of atrial natriuretic factor.8 Robillard and Weiner recently reported that acute volume expansion in human fetuses with immune haemolytic anaemia also resulted in increased concentrations of atrial natriuretic factor.9 In their study the highest concentration was in a fetus with severe anaemia and hydrops, and the concentrations decreased as the hydrops resolved. We have also reported similar preliminary findings.4

The objectives of this study were to determine whether human fetuses with varying degrees of hydrops fetalis and anaemia as a result of Rh isoimmunisation have increased concentrations of atrial natriuretic factor, and if those concentrations change after resolution of the hydrops by intravascular transfusion in utero.9

Material and methods
Umbilical venous blood samples were obtained from human fetuses about to undergo intra-vascular exchange transfusion in utero for severe anaemia caused by Rh isoimmunisation. This was done using an ultrasound guided percutaneous needle as previously described.9 All samples were taken before the start of the transfusion. Packed cell volume and haemoglobin concentration were measured with an automated cell counter.

Blood samples for plasma atrial natriuretic factor concentrations were collected in polypropylene tubes with heparin (1000 U/ml) and aprotinin (20 KIU/ml). After centrifugation plasma samples were stored at −80°C until analysis. Plasma atrial natriuretic factor concentrations were measured by radioimmunoassay (Peninsula Laboratories) using a previously described method.10 The interassay variability was 12.7% and intra-assay variation 6.1%. The recovery in all assays was over 80%.

Assessment of gestational age was based on last menstrual period and early ultrasound examination. Hydrops fetalis was diagnosed by ultrasound and was graded as follows: (i) absent, no evidence of ascites, pleural or pericardial effusion, or subcutaneous oedema; (ii) mild, a small amount of fluid in only one place (usually ascites); and (iii) severe, large amount of fluid in two or more places.

Statistical analysis was by one way and repeated measures analysis of variance (ANOVA), the Mann-Whitney U test and linear regression. When the data were skewed, they were analysed after logarithmic transformation. A probability of <0.05 was considered significant. All values are expressed as mean (SD).

Results
The study population comprised 15 fetuses with Rh isoimmunisation and one normal fetus who had samples taken at 38 weeks' gestation for determination of platelet count because of maternal immune thrombocytopenia. This fetus was normal on physical examination, and had a normal platelet count at delivery; the data were used not as a control but rather as an approximation of atrial natriuretic factor concentrations associated with normal haemoglobin concentrations. Blood was obtained from nine fetuses before they had received any transfusion in utero, whereas the other seven had had one or
Mean (SD) gestational ages and laboratory values in study group

<table>
<thead>
<tr>
<th></th>
<th>Fetuses without hydrops (n=5)</th>
<th>Fetuses with hydrops</th>
<th>F Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild (n=5)</td>
<td>Severe (n=8)</td>
<td></td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>33 (3)</td>
<td>31 (3)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>10 (0.11)</td>
<td>25 (4)</td>
<td></td>
</tr>
<tr>
<td>Packed cell volume</td>
<td>0.27 (0.038)</td>
<td>0.12 (0.056)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Haemoglobin (g/l)</td>
<td>89 (35)</td>
<td>64 (16)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Atrial natriuretic factor (pg/ml)</td>
<td>73.9 (39.4)</td>
<td>75.4 (42.6)</td>
<td>0.1</td>
</tr>
</tbody>
</table>

*Those with severe hydrops compared with the other two groups by ANOVA.

more transfusions in the weeks before samples were taken.

Eleven fetuses had ultrasonographic evidence of hydrops, and in eight of them it was severe (table). The remaining fetuses had no evidence of hydrops. Those with mild or no hydrops were more mature than those in which it was severe (p<0.01 by one way ANOVA). All fetuses with Rh isomunisation had packed cell volumes of less than 0.34 and haemoglobin concentrations below 110 g/l. Those fetuses with evidence of severe hydrops were significantly more anaemic than those in the other groups (p<0.01, one way ANOVA). Most fetuses with severe hydrops had higher concentrations of atrial natriuretic factor than fetuses with either no or mild hydrops, but because of the large variability this difference was not significant (p=0.1, Mann-Whitney test). When only the atrial natriuretic factor concentrations of fetuses from whom samples were taken before they received any transfusion in utero were analysed, however, those with severe hydrops (n=6) had significantly higher concentrations (755-2 (1030-6) pg/ml, range 126-2796) than fetuses with no or mild (n=3) hydrops (70-9 (45-8) pg/ml, range 39-9-123-6) (p<0.05, Mann-Whitney U test).

An inverse relationship was found between haemoglobin and atrial natriuretic factor concentrations by using linear regression after logarithmic transformation (y=2.68-9.85e-2x, p<0.02) (fig 1). This association was also present when the analysis included only atrial natriuretic factor concentrations in samples taken before exchange transfusion in utero (y=2.88-9.58e-2x, r²=0.51, p<0.05).

Five fetuses with severe hydrops were followed up serially. All showed complete resolution of both hydrops and severe anaemia after between two and five exchange transfusions in utero. In these fetuses the haemoglobin concentration increased from 34 (19) to 84 (13) g/l (p<0.005, repeated measures ANOVA). As the signs of hydrops disappeared, there was a significant decrease in concentrations of atrial natriuretic factor (p<0.02 by repeated measures ANOVA, fig 2).

**Discussion**

Immunoreactive atrial natriuretic factor has been found in the atria of human and rat fetuses early in gestation. This study, in common with several others, has shown that human fetuses under normal or pathological conditions have a wide range of circulating atrial natriuretic factor concentrations. Animal and human fetuses have higher concentrations of atrial natriuretic factor than their mothers. Although atrial natriuretic factor may cross the placenta, the small increases in maternal concentrations during pregnancy do not explain the pronounced increases that we found in fetuses with hydrops. Most evidence suggests that the placenta is not an important site of atrial natriuretic factor degradation, but arteriovenous differences in umbilical cord blood atrial natriuretic factor concentrations have been reported. Kojima et al reported mean (SD) normal cord blood atrial natriuretic factor values of 61-3 (22-5) pg/ml, which are lower than those found by Yamaji et al, of 165...
Atrial natriuretic factor in hydrops fetalis caused by Rh isoimmunisation

(27) pg/ml. Normal human fetuses studied by Robillard and Weiner between 22–26 weeks’ gestation had mean (SEM) plasma atrial natriuretic factor values of 90 (22) pg/ml. No changes in the concentration of atrial natriuretic factor with advancing gestational age have been reported.14 Our study group included only one normal fetus, but the circulating atrial natriuretic factor concentrations in this and other fetuses with mild anaemia and no evidence of hydrops were well within this range, suggesting that mild decreases in fetal haemoglobin concentrations are not associated with pronounced increases in circulating atrial natriuretic factor.

Hydrops fetalis commonly occurs when the fetal haemoglobin concentration drops below 60–70 g/l as in our study,7 but the hydrops can be reversed with intravascular intrauterine transfusions, which raise fetal haemoglobin concentrations. In Rh isoimmunisation fetal oedema results from the extensive erythropoiesis in the fetal liver that disrupts the portal circulation and impairs albumin synthesis,9,20 and perhaps also from the cardiovascular adaptations that are also seen in anaemic fetuses.21 Our data show that fetuses with severe hydrops had high atrial natriuretic factor concentrations and were also significantly more anaemic than those fetuses with either mild or no hydrops. In addition, an inverse relationship was found between the haemoglobin and atrial natriuretic factor concentrations.

Several factors may explain our findings. Firstly, as Rh isoimmunised fetuses become progressively more anaemic, their oxygen content is appreciably reduced. Haemoglobin concentrations of less than 40 g/l may lead to tissue hypoxia as measured by increased lactate concentration in the fetal circulation.22 Hypoxia may then result in myocardial dysfunction and increases in umbilical venous pressure, with subsequent release of atrial natriuretic factor.18 Although we did not measure blood gases or lactate, all our hydrop fetuses with severe hydrops and high atrial natriuretic factor concentrations had haemoglobin concentrations associated with tissue hypoxia.22 It is likely that the tissue hypoxia in severely anaemic fetuses results more from decreased oxygen content than from lower oxygen tensions (hypoxaemia); fetuses with immune haemolytic anaemia and hydrops have similar oxygen tensions to control fetuses.1 In sheep fetuses acute hypoxia produced by infusion of carbon dioxide to the maternal trachea is a potent stimulus for the release of atrial natriuretic factor.23 Thus it seems that tissue hypoxia resulting from either a low oxygen carrying capacity (severe anaemia) or hypoxaemia, may induce atrial natriuretic factor release. Whether one mechanism is more potent than the other, or whether chronic rather than acute changes in tissue oxygenation are responsible for atrial natriuretic factor release in Rh isoimmunised human fetuses is unknown.

Acute volume expansion in utero also increases circulating atrial natriuretic factor concentrations in both human and sheep fetuses.15 This is unlikely to explain our findings, as all samples were taken before the start of each procedure. Furthermore, hydropic fetuses are generally not hypervolaemic, but rather normovolaemic or hypoovalaemic.24–26 Arginine vasopressin and corticosteroids may also stimulate atrial natriuretic factor secretion.27 Weiner recently reported lower concentrations of arginine vasopressin in anaemic fetuses requiring transfusion than in those that were not anaemic.18 This makes atrial natriuretic factor release induced by arginine vasopressin a less likely explanation of our findings. Stimulation of atrial natriuretic factor release by sympathetic hormones is also unlikely, as human fetuses with Rh isoimmunisation have concentrations of adrenaline and noradrenaline comparable with control values.14 There were significant reductions in plasma atrial natriuretic factor concentrations after treatment with intravascular transfusions in utero, which resulted in appreciable improvement in haemoglobin concentrations and complete resolution of the hydrops. This suggests that as oxygen delivery improves the hypoxic stimulus for atrial natriuretic factor secretion ceases. An increase in atrial natriuretic factor degradation by the kidney or other fetal organs as the fetal condition improves, however, cannot be ruled out.

In summary we have shown that human fetuses with severe degrees of anaemia and hydrops fetalis have high concentrations of atrial natriuretic factor in plasma. These high concentrations decrease as the hydrops resolves and the haemoglobin concentration increases, with treatment by intravascular transfusion in utero. The pronounced increases in the concentration of atrial natriuretic factor in fetuses with severe anaemia may be the result of a hypoxic stimulus for the release of atrial natriuretic factor.

Moya, Grannum, Riddick, Robert, Pinheiro


Atrial natriuretic factor in hydrops fetalis caused by Rh isoimmunisation.

F R Moya, P A Grannum, L Riddick, J A Robert and J Pinheiro

*Arch Dis Child* 1990 65: 683-686
doi: 10.1136/adc.65.7_Spec_No.683

Updated information and services can be found at:
http://adc.bmj.com/content/65/7_Spec_No/683

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

### Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/